Results 11 to 20 of about 1,373 (139)

Colin Rowe y el equilibrio dinámico

Cuadernos de Proyectos Arquitectónicos, 2015
ResumenEn 1944 Gyorgy Kepes publica el que sin duda será su texto más influyente, El lenguaje de la visión. En él Kepes trata de llevar a cabo una guía que explique la gramática y la sintaxis del fenómeno de la visión, y que sirva como herramienta para ...
Pablo López Martín
doaj   +2 more sources

Ambichronous historiography: Colin Rowe and the teaching of architectural history [PDF]

Journal of Art Historiography, 2016
Ianus Architectus is the Latin combination of the Architect with the ancient Roman god of beginnings and ends, pasts and futures, Janus. It represents the dual act of both seeing past-and-future (Janus’ two faces), and producing (architecture ...
Braden Engel
doaj   +1 more source

When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 Years. [PDF]

Ann Neurol
Objective Sporadic late‐onset Alzheimer's disease (AD) is characterized by a long pre‐clinical phase where amyloid‐beta (Aβ) and tau begin to accumulate in the brain. The primary objective was to determine the age at which AD starts by finding the average population age when both positron emission tomography (PET) Aβ (Aβ‐PET) and plasma Aβ42/40 become ...
Cánovas R, Cox T, Doré V, Bourgeat P, Fripp J, Feizpour A, Shishegar R, Fowler CJ, Laws SM, Porter T, Rainey-Smith S, Shaw LM, Bateman RJ, Li Y, Vitaliy O, Weiner MW, Morris JC, Benzinger TLS, Schindler SE, Nakamura A, Iwatsubo T, Ikeuchi T, Kato T, Maruff P, Sohrabi HR, Rowe CC, Martins RN, Masters CL, Doecke JD, Alzheimer's Disease Neuroimaging Initiative.   +29 more
europepmc   +2 more sources

Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories. [PDF]

Alzheimers Dement
Abstract INTRODUCTION With increased uptake in disease‐modifying treatments for amyloid beta (Aβ) removal, it is important to measure performance of highly sensitive plasma biomarkers to detect the presence of Aβ and tau in cognitively impaired populations.
Cánovas R, Fowler CJ, Feizpour A, Dóre V, Bourgeat P, Saad ZS, Triana-Baltzer G, Kolb HC, Vandijck M, Kollmorgen G, Quijano-Rubio C, Fripp J, Laws S, Bannon AW, Blennow K, Zetterberg H, Rainey-Smith S, Mathotaarachchi S, Rowe CC, Masters CL, Doecke JD, AIBL Research Group.   +21 more
europepmc   +2 more sources

Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease. [PDF]

Alzheimers Dement
Abstract INTRODUCTION The cholinergic basal forebrain system, particularly the nucleus basalis of Meynert (Ch4), is selectively vulnerable to amyloid beta (Aβ) and tau in Alzheimer's disease (AD). Their interplay may be a critical driver of AD progression, but remains poorly understood. METHODS Data from 779 older individuals in the Australian Imaging,
Xia Y, Dean MW, Bourgeat P, Krishnadas N, Maruff P, Masters CL, Villemagne VL, Fripp J, Rowe CC, Doré V, Coulson EJ.   +10 more
europepmc   +2 more sources

Harmonizing neuropsychological test data across prospective studies. [PDF]

Alzheimers Dement
Abstract INTRODUCTION Alzheimer's disease (AD) research relies on large datasets and advanced statistical models. However, individual population studies often lack sufficient sample size for conclusive results. Harmonizing cognitive test data across studies can address this gap, despite differences in testing protocols.
Shishegar R, Doecke JD, Lim YY, Bourgeat P, Dore V, Tallapragada B, Laws SM, Porter T, Burnham S, Feizpour A, Gillman A, Weiner M, Hassenstab J, Rowe CC, Villemagne VL, Masters CL, Fripp J, Sohrabi H, Maruff P, Alzheimer's Disease Neuroimaging Initiative, OASIS‐3, and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing.   +21 more
europepmc   +2 more sources

CenTauR correlation with amyloid, atrophy and cognition across the Alzheimer's Disease spectrum: A tau imaging study with 18F‐MK6240 PET [PDF]

Alzheimers Dement
Abstract Background The CenTauR (CTR) standard method for PET measurement of tau provides consistent results across tau tracers. This study establishes regional CTR thresholds for elevated tau and evaluates the CTR relationship with amyloid, neurodegeneration and cognition across the AD spectrum.
Rowe C, Feizpour A, Bourgeat P, Leuzy A, Mulligan R, Robertson J, Laws S, Martins R, Maruff P, Masters C, Fripp J, Villemagne V, Dore V.   +12 more
europepmc   +3 more sources

Using AI to improve cross‐sectional and longitudinal Amyloid PET quantification: A validation study across 7 large cohorts [PDF]

Alzheimers Dement
Abstract Background Centiloid quantification relies on a Standardised Uptake Value Ratio (SUVR) that could be subject to noise, spill‐in, and specific binding in the reference region. We developed a novel deep learning method that learns scan‐specific variability from longitudinal trends to correct SUVR quantification and then validated it in 7 large ...
Bourgeat P, Fripp J, Gillman A, Cox T, Feizpour A, Xia Y, Zisis G, Goyal M, Tosun D, LaMontagne P, Benzinger T, Barkhof F, Farrar G, Bollack A, Sperling R, Morris J, Weiner M, Villemagne V, Masters C, Rowe C, Dore V.   +20 more
europepmc   +3 more sources

Diagramming Urban Fragments: Collage City and the ‘Vest-pocket’ in the Case Study of Canberra [PDF]

Athens Journal of Architecture, 2023
Written as part of the reaction to Modernist planning in the late 1970s, Collage City by Colin Rowe and Fred Koetter proposes an urban design theory which applies collage as a method from art, shifting the focus from the scale of the totality down to the
Viktoria Holmik, Milica Muminovic
doaj   +1 more source

Sensitivity of cognitive composite scores to amyloid accumulation in emergent Alzheimer's disease [PDF]

Alzheimers Dement
Abstract Background In clinical trials for preclinical Alzheimer's disease (AD), cognition is the primary outcome and is measured by preclinical Alzheimer's disease cognitive composite (PACC) scores that combine data from neuropsychological tests of memory and executive function and clinical mental status.
Xia Y, Dore V, Fripp J, Bourgeat P, Lim Y, Robertson J, Rowe C, Masters C, Maruff P.   +8 more
europepmc   +2 more sources